Our Team


James Hackworth, PhD

Founder, CEO & Chairman

James Hackworth, PhD - Dr. Hackworth is a pharmaceutical executive with an extensive track record in licensing, M&A, and partnership transactions, particularly ones with a high degree of complexity, and pharmaceutical commercialization and is an expert on the US pain market.  He began his career in strategy consulting with McKinsey and Company and recently served as Senior Vice President of Corporate Development and Commercialization Strategy at Shionogi, Inc.  He helped Shionogi remake its US business through a series of transactions over several years and the commercial strategy and execution for launching several drugs generated from its pipeline.  Currently, in addition to Park, Dr Hackworth serves as Chief Business Officer for DeepBiome Therapeutics, is a Mid-Atlantic Bio-Angles Steering Committee member, and is a Board member for Elysium Therapeutics. He graduated summa cum laude with a BS in physics from the Ohio State University in 1998 and a PhD in theoretical physics from Columbia University in 2006. 


Marc Lesnick, PhD

Co-Founder, Chief Development Officer &

Board Member

Marc Lesnick, PhD- Dr. Lesnick has over 20 years of experience in clinical development, regulatory affairs and quality, with multiple prior successful marketing applications in the United States and Europe. Dr. Lesnick has worked in multiple therapeutic areas including pain, oncology and infectious disease, and has experience with products at all stages of development, as well as with the product launches of Dificid®, Osphena® and other drugs. He has been part of executive teams involved in successful acquisitions at both Cascadian Therapeutics and at Optimer Pharmaceuticals.

Dr. Lesnick was most recently VP of Regulatory and Quality at Spruce Biosciences, which successfully IPO'd in 2020.  Before this, he served as the Sr. Vice President of Regulatory Affairs and Quality at Cascadian Therapeutics until its acquisition by Seattle Genetics.  He also served as the Senior Vice President, U.S. Regulatory Affairs, Global Development Projects at Shionogi, Inc. Dr. Lesnick received his PhD from the University of Oregon and performed his post-doctoral work at the UCSD School of Medicine.


Ketan Mehta

Board Member

Mr. Mehta is the founder and CEO of Tris Pharma, a specialty pharmaceutical company. Under his leadership, Tris has developed many innovative formulation technologies, launched new products, and established itself as a leader among technology-driven pharmaceutical companies. Ketan’s work at Tris has led to many discoveries and inventions. Before founding Tris Pharma, Ketan worked for Capsugel (formerly a division of Pfizer) in sales, marketing, and business development for eight years. Prior to Capsugel, he spent approximately six years as a pharmaceutical scientist for three different large pharmaceutical companies. Ketan is a pharmacist by education and holds an MS degree in Pharmaceutical Sciences from the University of Oklahoma.